Published in Eur J Clin Pharmacol on February 11, 2015
A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice. Expert Rev Clin Pharmacol (2013) 0.89
CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults. Can J Infect Dis Med Microbiol (2013) 0.84
Psychiatric treatment considerations with direct acting antivirals in hepatitis C. BMC Gastroenterol (2013) 0.78
Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction. Eur J Clin Pharmacol (2016) 0.76
Rifampicin decreases exposure to sublingual buprenorphine in healthy subjects. Pharmacol Res Perspect (2016) 0.75
Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med (2011) 12.09
Ethnic differences in N-glucuronidation of nicotine and cotinine. J Pharmacol Exp Ther (1999) 2.14
Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet (2002) 1.96
Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. J Acquir Immune Defic Syndr (2006) 1.73
Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology (2012) 1.64
Methadone--metabolism, pharmacokinetics and interactions. Pharmacol Res (2004) 1.53
A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology (2004) 1.52
Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet (2005) 1.43
In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters. Drug Metab Dispos (2013) 1.42
Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor. Drug Metab Dispos (2010) 1.05
Determination of naloxone and nornaloxone (noroxymorphone) by high-performance liquid chromatography-electrospray ionization- tandem mass spectrometry. J Anal Toxicol (2009) 0.97
Glucuronidation of buprenorphine and norbuprenorphine by human liver microsomes and UDP-glucuronosyltransferases. Drug Metab Lett (2009) 0.96
Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir. Clin Infect Dis (2012) 0.92
Efficacy and safety of peginterferon alfa-2a/ribavirin in methadone maintenance patients: randomized comparison of direct observed therapy and self-administration. Am J Gastroenterol (2008) 0.91
A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice. Expert Rev Clin Pharmacol (2013) 0.89
Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. Drug Alcohol Depend (2009) 0.83
Peginterferon alfa-2a does not alter the pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy. Clin Pharmacol Ther (2005) 0.83
Pharmacokinetic interaction between telaprevir and methadone. Antimicrob Agents Chemother (2013) 0.81
Pharmacokinetic evaluation of the interaction between hepatitis C virus protease inhibitor boceprevir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and pravastatin. Antimicrob Agents Chemother (2013) 0.80
Investigation of the interactions between methadone and elvitegravir-cobicistat in subjects receiving chronic methadone maintenance. Antimicrob Agents Chemother (2013) 0.76
Tipranavir/ritonavir induction of buprenorphine glucuronide metabolism in HIV-negative subjects chronically receiving buprenorphine/naloxone. Am J Drug Alcohol Abuse (2011) 0.75
Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem (2003) 5.40
Reducing the health consequences of opioid addiction in primary care. Am J Med (2013) 3.44
Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res (2006) 2.96
Concerns about injectable naltrexone for opioid dependence. Lancet (2011) 2.92
Opioid pharmacotherapy for chronic non-cancer pain in the United States: a research guideline for developing an evidence-base. J Pain (2010) 2.90
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther (2005) 2.85
Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology (2002) 2.72
Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab (2006) 2.64
Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial. Clin Infect Dis (2007) 2.37
Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos (2007) 2.17
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. Ann Intern Med (2015) 2.13
A 1-year prospective clinical study of soft tissue conditions and marginal bone changes around dental implants after flapless implant surgery. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2010) 2.10
A targeted intervention for the career development of women in academic medicine. Arch Intern Med (2007) 2.09
Benzodiazepines in long-term opioid therapy. Pain Med (2013) 2.03
HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr (2011) 1.97
Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir. Clin Infect Dis (2012) 1.91
Retinoids regulate stem cell differentiation. J Cell Physiol (2011) 1.91
ATPgammaS enhances the production of inflammatory mediators by a human dermal endothelial cell line via purinergic receptor signaling. J Invest Dermatol (2006) 1.76
[18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc Natl Acad Sci U S A (2007) 1.73
The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS (2004) 1.73
Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression. Sci Transl Med (2012) 1.71
A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer. Clin Cancer Res (2006) 1.71
Integration and co-location of HIV/AIDS, tuberculosis and drug treatment services. Int J Drug Policy (2007) 1.65
Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology (2012) 1.64
Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension. Antimicrob Agents Chemother (2012) 1.57
Pharmacokinetics of ertapenem in patients with varying degrees of renal insufficiency and in patients on hemodialysis. J Clin Pharmacol (2006) 1.56
Models for integrating buprenorphine therapy into the primary HIV care setting. Clin Infect Dis (2006) 1.55
Case records of the Massachusetts General Hospital. Case 8-2007. A 48-year-old man with chest pain followed by cardiac arrest. N Engl J Med (2007) 1.53
Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation. J Clin Pharmacol (2007) 1.51
Bioactive compounds from marine bacteria and fungi. Microb Biotechnol (2010) 1.46
A review and assessment of potential sources of ethnic differences in drug responsiveness. J Clin Pharmacol (2003) 1.46
Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report. Pharm Res (2005) 1.44
Effects of omeprazole on plasma levels of raltegravir. Clin Infect Dis (2009) 1.43
Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects. Antimicrob Agents Chemother (2008) 1.41
Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol (2008) 1.40
Effects of laropiprant, a selective prostaglandin D(2) receptor 1 antagonist, on the pharmacokinetics of rosiglitazone. Cardiovasc Ther (2009) 1.40
Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor. J Clin Pharmacol (2011) 1.38
Buprenorphine/Naloxone and methadone effects on laboratory indices of liver health: a randomized trial. Drug Alcohol Depend (2012) 1.37
Impact of enhanced services on virologic outcomes in a directly administered antiretroviral therapy trial for HIV-infected drug users. J Acquir Immune Defic Syndr (2006) 1.33
Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother (2009) 1.24
Effect of low-, moderate-, and high-fat meals on raltegravir pharmacokinetics. J Clin Pharmacol (2010) 1.22
Atazanavir modestly increases plasma levels of raltegravir in healthy subjects. Clin Infect Dis (2008) 1.21
Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol (2006) 1.19
Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib. J Lipid Res (2011) 1.18
Opening up to precompetitive collaboration. Sci Transl Med (2010) 1.18
Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother (2008) 1.16
Identifying programmatic gaps: inequities in harm reduction service utilization among male and female drug users in Dar es Salaam, Tanzania. PLoS One (2013) 1.12
Lack of a significant drug interaction between raltegravir and tenofovir. Antimicrob Agents Chemother (2008) 1.11
Clinical management of depression and anxiety in HIV-infected adults. AIDS (2005) 1.11
Initiation, adherence, and retention in a randomized controlled trial of directly administered antiretroviral therapy. AIDS Behav (2007) 1.11
A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manage (2006) 1.11
Calcitonin gene-related peptide biases Langerhans cells toward Th2-type immunity. J Immunol (2008) 1.09
Long-term safety of NGX-4010, a high-concentration capsaicin patch, in patients with peripheral neuropathic pain. J Pain Symptom Manage (2010) 1.08
Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Br J Clin Pharmacol (2009) 1.07
Physiological and therapeutic roles of peroxisome proliferator-activated receptors. Diabetes Technol Ther (2002) 1.06
Integrating care for hepatitis C virus (HCV) and primary care for HIV for injection drug users coinfected with HIV and HCV. Clin Infect Dis (2005) 1.05
Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. J Clin Endocrinol Metab (2007) 1.04
Catecholamines inhibit the antigen-presenting capability of epidermal Langerhans cells. J Immunol (2002) 1.04
A cost-effectiveness approach to the qualification and acceptance of biomarkers. Nat Rev Drug Discov (2006) 1.03
Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics. Antimicrob Agents Chemother (2009) 1.02
Behavioral counseling content for optimizing the use of buprenorphine for treatment of opioid dependence in community-based settings: a review of the empirical evidence. Am J Drug Alcohol Abuse (2007) 1.02
Comprehensive consensus based guidelines on intrathecal drug delivery systems in the treatment of pain caused by cancer pain. Pain Physician (2011) 1.02
Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans. Drug Metab Dispos (2007) 1.01
A novel murine infection model for Shiga toxin-producing Escherichia coli. J Clin Invest (2012) 1.01
Accelerating drug development using biomarkers: a case study with sitagliptin, a novel DPP4 inhibitor for type 2 diabetes. AAPS J (2008) 0.99
Research design considerations for clinical studies of abuse-deterrent opioid analgesics: IMMPACT recommendations. Pain (2012) 0.99
Directly administered antiretroviral therapy for HIV-infected drug users does not have an impact on antiretroviral resistance: results from a randomized controlled trial. J Acquir Immune Defic Syndr (2007) 0.99
Retention on buprenorphine treatment reduces emergency department utilization, but not hospitalization, among treatment-seeking patients with opioid dependence. J Subst Abuse Treat (2012) 0.98
Augmentation of cutaneous immune responses by ATP gamma S: purinergic agonists define a novel class of immunologic adjuvants. J Immunol (2005) 0.97
Renal injury is a consistent finding in Dutch Belted rabbits experimentally infected with enterohemorrhagic Escherichia coli. J Infect Dis (2006) 0.97
Impaired toll-like receptor 3-mediated immune responses from macrophages of patients chronically infected with hepatitis C virus. Clin Vaccine Immunol (2012) 0.96
Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir. AIDS (2006) 0.95
Effect of tipranavir-ritonavir on pharmacokinetics of raltegravir. Antimicrob Agents Chemother (2009) 0.95
Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males. Br J Clin Pharmacol (2011) 0.94
Effects of a niacin receptor partial agonist, MK-0354, on plasma free fatty acids, lipids, and cutaneous flushing in humans. J Clin Lipidol (2008) 0.94
CGRP, PACAP, and VIP modulate Langerhans cell function by inhibiting NF-kappaB activation. J Invest Dermatol (2007) 0.93
Safety and pharmacokinetics of higher doses of caspofungin in healthy adult participants. J Clin Pharmacol (2010) 0.93
Definitions and outcome measures of clinical trials regarding opioid-induced constipation: a systematic review. J Clin Gastroenterol (2015) 0.92
An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans. Neuropsychopharmacology (2013) 0.92
Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies in healthy volunteers. Br J Clin Pharmacol (2013) 0.92
Association of GSTM1 null allele with prostate cancer risk: evidence from 36 case-control studies. PLoS One (2012) 0.91
Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor. Cancer Chemother Pharmacol (2013) 0.91
A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects. J Clin Pharmacol (2009) 0.90
A pharmacokinetic comparison of adult and paediatric formulations of raltegravir in healthy adults. Antivir Ther (2014) 0.90
Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women. Br J Clin Pharmacol (2011) 0.89
Assessment of the CYP3A-mediated drug interaction potential of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy volunteers. J Clin Pharmacol (2008) 0.89
Tolerability of NGX-4010, a capsaicin 8% patch for peripheral neuropathic pain. J Pain Res (2011) 0.89
A high-precision fluorogenic cholesteryl ester transfer protein assay compatible with animal serum and 3456-well assay technology. Anal Biochem (2007) 0.88
Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin. Can J Clin Pharmacol (2009) 0.88
Accelerating cancer therapy development: the importance of combination strategies and collaboration. Summary of an Institute of Medicine workshop. Clin Cancer Res (2012) 0.88
Pharmacokinetics and pharmacodynamics of MK-5046, a bombesin receptor subtype-3 (BRS-3) agonist, in healthy patients. J Clin Pharmacol (2011) 0.88
Norepinephrine modulates human dendritic cell activation by altering cytokine release. Exp Dermatol (2008) 0.88
Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects. J Clin Pharmacol (2008) 0.88
The effect of hOGG1 Ser326Cys polymorphism on cancer risk: evidence from a meta-analysis. PLoS One (2011) 0.88